medac Gesellschaft fur klinische Specialpraparate GmbH

Poland

All drugs from this manufacturer

  • HYDROXYUREA MEDAC

    The medicine is used in the treatment of chronic myeloid leukemia (in the chronic or accelerated phase) and in the treatment of essential thrombocythemia or polycythemia vera, if there is a high risk of thromboembolic complications.

    Dosage form: capsules, hard

    Active substance Dosage
    hydroxyurea 500 mg

    ATC: L01XX05